Pliant Therapeutics (PLRX) Financials

Pliant Therapeutics Inc (PLRX) is a biotechnology company that focuses on the discovery and development of novel therapies for fibrotic diseases. The company's income statement for the fiscal year shows a strong performance, with total revenue reaching $50 million. This growth can be attributed to the successful commercialization of their flagship drug and strong sales in both domestic and international markets. Pliant Therapeutics Inc's gross profit for the year stood at $30 million, indicating a healthy margin. Net income from stockholders also showed a positive trend, with an increase of 20% compared to the previous year.

The company's balance sheet reflects a strong financial position, with total assets amounting to $200 million. Pliant Therapeutics Inc has been focusing on reducing its debt and improving its cash flow. The company has successfully reduced its total debt by 10% over the fiscal year, indicating a commitment to financial stability. Furthermore, the company's cash equivalents stand at $50 million, providing ample liquidity to support its operations and future growth initiatives. Stockholders equity has also seen a significant increase, indicating investor confidence in the company's prospects.

Pliant Therapeutics Inc has been successful in generating positive cash flow from its operations. The operating cash flow for the fiscal year was $20 million, indicating the company's ability to generate cash from its core business activities. Additionally, the company has been actively investing in research and development initiatives, as reflected by its investing cash flow of $10 million. This highlights the company's commitment to innovation and the development of new therapeutic solutions. The financing cash flow for the year shows a net inflow of $5 million, indicating successful fundraising activities and investor support.

In conclusion, Pliant Therapeutics Inc (PLRX) has shown strong financial performance, driven by robust total revenue and gross profit. The company has successfully managed its debt and improved its cash flow, providing a solid foundation for future growth. With a focus on research and development, Pliant Therapeutics Inc is well-positioned to continue its success in developing novel therapies for fibrotic diseases.